PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: PIPELINE ANALYSIS
• Pipeline analysis
PART 05: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Topical – Market size and forecast 2018-2023
• Oral – Market size and forecast 2018-2023
• Market opportunity by product
PART 08: CUSTOMER LANDSCAPE
PART 09: SEGMENTATION BY DRUG CLASS
PART 10: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 13: MARKET TRENDS
• Market trends
PART 14: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 15: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Cutanea Life Sciences
• GlaxoSmithKline
• LEO Pharma
• Medimetriks Pharmaceuticals
PART 16: APPENDIX
• Research methodology
• List of abbreviations
PART 17: EXPLORE TECHNAVIO
Exhibit 01: Global dermatological drugs market
Exhibit 02: Segments of global dermatological drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition – Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition – Five forces 2018
Exhibit 17: Product – Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: Topical – Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Topical – Year-over-year growth 2019-2023 (%)
Exhibit 21: Oral – Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Oral – Year-over-year growth 2019-2023 (%)
Exhibit 23: Market opportunity by product
Exhibit 24: Customer landscape
Exhibit 25: Market share by geography 2018-2023 (%)
Exhibit 26: Geographic comparison
Exhibit 27: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 29: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 30: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 31: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 32: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 33: Key leading countries
Exhibit 34: Market opportunity
Exhibit 35: Impact of drivers and challenges
Exhibit 36: Vendor landscape
Exhibit 37: Landscape disruption
Exhibit 38: Vendors covered
Exhibit 39: Vendor classification
Exhibit 40: Market positioning of vendors
Exhibit 41: Cutanea Life Sciences – Vendor overview
Exhibit 42: Cutanea Life Sciences – Organizational developments
Exhibit 43: Cutanea Life Sciences – Key offerings
Exhibit 44: GlaxoSmithKline – Vendor overview
Exhibit 45: GlaxoSmithKline – Business segments
Exhibit 46: GlaxoSmithKline – Organizational developments
Exhibit 47: GlaxoSmithKline – Geographic focus
Exhibit 48: GlaxoSmithKline – Segment focus
Exhibit 49: GlaxoSmithKline – Key offerings
Exhibit 50: LEO Pharma – Vendor overview
Exhibit 51: LEO Pharma – Organizational developments
Exhibit 52: LEO Pharma – Geographic focus
Exhibit 53: LEO Pharma – Key offerings
Exhibit 54: Medimetriks Pharmaceuticals – Vendor overview
Exhibit 55: Medimetriks Pharmaceuticals – Organizational developments
Exhibit 56: Medimetriks Pharmaceuticals – Key offerings
【掲載企業】
Cutanea Life Sciences、GlaxoSmithKline、LEO Pharma、Medimetriks Pharmaceuticals